Relationship between positive inotropic responses and plasma concentrations of xamoterol in middle-aged and elderly patients
- PMID: 2140946
- PMCID: PMC1380149
- DOI: 10.1111/j.1365-2125.1990.tb03673.x
Relationship between positive inotropic responses and plasma concentrations of xamoterol in middle-aged and elderly patients
Abstract
1. We examined the relationship between the contractile state of the left ventricle and the plasma concentration of xamoterol in patients with ischaemic heart failure. 2. Identical studies were conducted in 14 middle-aged (all male; mean age 51.3 years, range 42-61) and 10 elderly patients (six male, four female; mean age 67.7 years, range 64-72). 3. Patients received seven cumulative doses (0.0005-0.2 mg kg-1) of xamoterol. After each dose the rate of change of pressure in the left ventricle at a developed pressure of 40 mm Hg and normalised for this pressure, (dP/dt)/DP40, and plasma concentrations of xamoterol were measured. 4. There were dose-related increases in (dP/dt)/DP40. Curves relating changes in (dP/dt)/DP40, expressed as a percent of the maximum observed response, to changes in xamoterol plasma concentrations were constructed for the middle-aged and elderly patients. From these curves the mean effective concentration (EC) value to produce a particular response could be calculated. In the sample sizes studied, the difference between the EC values over a range of responses for the middle-aged and elderly patients did not reach statistical significance, indicating that cardiac responsiveness to xamoterol was similar in the two groups of patients. 5. Plasma concentrations of xamoterol over the range of 39 to 150 ng ml-1 produced positive inotropic responses which varied between 70% and 90% of the maximum observed effect of xamoterol.
Similar articles
-
Effects of the beta 1-adrenergic receptor partial agonist xamoterol on left ventricular diastolic function. An evaluation after 1-6 years of oral therapy.Circulation. 1990 Feb;81(2 Suppl):III87-92. Circulation. 1990. PMID: 1967560
-
The effect of oral dosing of xamoterol on systolic time intervals in man and xamoterol plasma concentrations in heart failure patients.Br J Clin Pharmacol. 1990 Apr;29(4):447-53. doi: 10.1111/j.1365-2125.1990.tb03663.x. Br J Clin Pharmacol. 1990. PMID: 2139340 Free PMC article. Clinical Trial.
-
The cardiovascular effects of xamoterol, a beta 1-adrenoceptor partial agonist, in healthy volunteers at rest.Br J Clin Pharmacol. 1986 Mar;21(3):259-65. doi: 10.1111/j.1365-2125.1986.tb05188.x. Br J Clin Pharmacol. 1986. PMID: 2421751 Free PMC article. Clinical Trial.
-
Beta, partial agonists to treat heart failure: effects of xamoterol upon cardiac function and clinical status.Clin Cardiol. 1990 Mar;13(3):171-6. doi: 10.1002/clc.4960130305. Clin Cardiol. 1990. PMID: 1969783 Review.
-
The pharmacology of xamoterol: a basis for modulation of the autonomic control of the heart.Br J Clin Pharmacol. 1989;28 Suppl 1(Suppl 1):3S-13S. doi: 10.1111/j.1365-2125.1989.tb03569.x. Br J Clin Pharmacol. 1989. PMID: 2572252 Free PMC article. Review.
Cited by
-
The lipolytic effect of beta 1- and beta 2-adrenoceptor activation in healthy human volunteers.Br J Clin Pharmacol. 1993 Jan;35(1):35-9. doi: 10.1111/j.1365-2125.1993.tb05667.x. Br J Clin Pharmacol. 1993. PMID: 8383517 Free PMC article. Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical